Mylan Pharmaceuticals Inc. and the Centers for Medicare and Medicaid Services are in disagreement over whether Mylan’s EpiPen (epinephrine) emergency treatment for severe allergic reactions is appropriately classified as a “non-innovator” drug in Medicaid and therefore subject to a generic-level base pricing rebate.
The base rebate for generics is 13%, well below the 23.1% base rebate required for innovator (branded) drugs in Medicaid...







